Trials / Unknown
UnknownNCT05055167
Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC
A Phase II Study of Envafolimab as First-line Treatment of Aged Patients With High PD-L1 Expression Stage in Advanced Non-small-cell Lung Cancer(NSCLC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
Explore the efficacy and safety of Envafolimab in first line treatment of elderly patients with locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression, view to providing better treatment options for elderly patients with high PD-L1 expression and improving the survival and prognosis of patients .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Envafolimab | single agent, 300mg Q3W IH until disease progressed |
Timeline
- Start date
- 2021-08-30
- Primary completion
- 2024-12-30
- Completion
- 2025-06-30
- First posted
- 2021-09-24
- Last updated
- 2021-09-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05055167. Inclusion in this directory is not an endorsement.